e-learning
resources
Vienna 2009
Sunday, 13.09.2009
Respiratory infection caused by Pseudomonas aeruginosa
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Pseudomonas aeruginosa and antibiotic resistance in acute exacerbations of COPD (AECOPD)
D. R. Monserrate Mitchell, E. Prats Soro, M. Lopez Sanchez, F. Manresa Presas (Spain)
Source:
Annual Congress 2009 - Respiratory infection caused by Pseudomonas aeruginosa
Session:
Respiratory infection caused by Pseudomonas aeruginosa
Session type:
Oral Presentation
Number:
1365
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. R. Monserrate Mitchell, E. Prats Soro, M. Lopez Sanchez, F. Manresa Presas (Spain). Pseudomonas aeruginosa and antibiotic resistance in acute exacerbations of COPD (AECOPD). Eur Respir J 2009; 34: Suppl. 53, 1365
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Pseudomonas aeruginosa
drug susceptibility in patients hospitalized with COPD exacerbation and bronchiectasis
Source: Eur Respir J 2001; 18: Suppl. 33, 541s
Year: 2001
Acute exacerbations of COPD due to pseudomonas aeruginosa: Impact of antimicrobial resistance
Source: International Congress 2015 – Infection in COPD: different aspects of the host/pathogen balance
Year: 2015
Severe exacerbations of chronic obstructive pulmonary disease (COPD) due to
Pseudomonas aeruginosa
: resistance to common antibiotics
Source: Eur Respir J 2001; 18: Suppl. 33, 540s
Year: 2001
Pseudomonas aeruginosa in patients hospitalised for COPD exacerbation: a prospective study
Source: Eur Respir J 2009; 34: 1072-1078
Year: 2009
The impact of pseudomonas aeruginosa in the sputum of patients presenting with acute COPD exacerbation
Source: Annual Congress 2004 - Role of infection in COPD
Year: 2004
COPD and
pseudomonas aeruginosa
, an association
Source: International Congress 2014 – Resistance, bacteriological profile and comorbidities in respiratory infections
Year: 2014
The clinical impact of nebulised antibiotics in adults with bronchiectasis and chronic pseudomonas aeruginosa
Source: Virtual Congress 2020 – Non-tuberculous mycobacterial infections and bronchiectasis
Year: 2020
Influence of biofim on the bronchial microbiome in COPD patients colonized or infected by pseudomonas aeruginosa
Source: International Congress 2015 – Advances from translational research in respiratory infections
Year: 2015
Impact of Pseudomonas aeruginosa on exacerbation and death in patients with chronic obstructive pulmonary disease.
Source: International Congress 2019 – Airway infection in COPD
Year: 2019
Inhaled corticosteroid use and its association with Pseudomonas aeruginosa infection in COPD
Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies
Year: 2021
Bacterial infections in patients with acute exacerbations of COPD
Source: Eur Respir J 2004; 24: Suppl. 48, 639s
Year: 2004
Inhaled phage therapy for the treatment of acute Pseudomonas aeruginosa lung infections
Source: International Congress 2018 – Mechanisms of respiratory infection
Year: 2018
Antibacterial activity of telithromycin (TEL) and comparators against bacterial pathogens isolated from patients with acute exacerbations of chronic bronchitis (AECB) in the PROTEKT study 1999–2002
Source: Eur Respir J 2004; 24: Suppl. 48, 641s
Year: 2004
Antibacterial activity of telithromycin and comparators against pathogens isolated from patients with acute exacerbations of chronic bronchitis (AECB) in PROTEKT years 1–5 (1999–2004)
Source: Annual Congress 2006 - Clinical aspects and treatment of lower respiratory infection in COPD patients
Year: 2006
Antibiotic treatment and prevention of exacerbations of COPD
Source: Eur Respir Monogr 2013; 60: 96-106
Year: 2013
Persistence and genetic adaptation of Pseudomonas aeruginosa in patients with COPD.
Source: Virtual Congress 2020 – Airway infection: the microbiome and beyond
Year: 2020
Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study
Source: Eur Respir J 2013; 41: 1107-1115
Year: 2013
The effect of erythromycin on the chronic lower airway infection by pseudomonas aeruginosa
Source: Eur Respir J 2004; 24: Suppl. 48, 640s
Year: 2004
COPD: antibiotic strategy in infectious exacerbations
Source: Eur Respir J 2001; 18: Suppl. 33, 137s
Year: 2001
Etiology of exacerbations in severe COPD patients with bronchial chronic colonization by pseudomonas
Source: Annual Congress 2013 –Difficult and rare respiratory infections
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept